Literature DB >> 11500230

Bovine mastitis and intramammary drug delivery: review and perspectives.

P Gruet1, P Maincent, X Berthelot, V Kaltsatos.   

Abstract

Intramammary infections (IMIs) represent a major feature in bovine pathology. The treatment of IMIs concern antimicrobial substances. Therapeutic strategies involve administration of immediate release formulations during lactation with or without long-acting formulations during the dry period. Current treatments are not very successful and cure rates are poor, especially towards Staphylococcus aureus which is responsible for chronic infections and huge economic losses. New strategies have recently been investigated. These include particular immunomodulators like lysostaphin or cytokines, and novel formulations (e.g. liposomes, microparticles or nanoparticles) that allow uptake of the active component by phagocytes and thus prolong an enhanced antibacterial activity.

Entities:  

Mesh:

Year:  2001        PMID: 11500230     DOI: 10.1016/s0169-409x(01)00160-0

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  36 in total

1.  Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands.

Authors:  Mathias Schmelcher; Anne M Powell; Stephen C Becker; Mary J Camp; David M Donovan
Journal:  Appl Environ Microbiol       Date:  2012-01-27       Impact factor: 4.792

Review 2.  Recombinant bacteriophage lysins as antibacterials.

Authors:  Mark Fenton; Paul Ross; Olivia McAuliffe; Jim O'Mahony; Aidan Coffey
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

Review 3.  The nipple: a simple intersection of mammary gland and integument, but focal point of organ function.

Authors:  Sachiko Koyama; Hsin-Jung Wu; Teresa Easwaran; Sunil Thopady; John Foley
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-05-15       Impact factor: 2.673

4.  Design and characterisation of a polyethylene oxide matrix with the potential use as a teat insert for prevention/treatment of bovine mastitis.

Authors:  Sushila Bhattarai; Raid G Alany; Craig R Bunt; Hamdy Abdelkader; Michael J Rathbone
Journal:  AAPS J       Date:  2014-10-16       Impact factor: 4.009

5.  Synergistic streptococcal phage λSA2 and B30 endolysins kill streptococci in cow milk and in a mouse model of mastitis.

Authors:  Mathias Schmelcher; Anne M Powell; Mary J Camp; Calvin S Pohl; David M Donovan
Journal:  Appl Microbiol Biotechnol       Date:  2015-04-21       Impact factor: 4.813

6.  Prevalence and risk factors of subclinical mastitis in lactating dairy cows in north and south regions of Bangladesh.

Authors:  Swapan Chandra Sarker; Mst Sonia Parvin; A K M Anisur Rahman; Md Taohidul Islam
Journal:  Trop Anim Health Prod       Date:  2012-12-31       Impact factor: 1.559

7.  Evaluation of humoral immunity and protective efficacy of biofilm producing Staphylococcus aureus bacterin-toxoid prepared from a bovine mastitis isolate in rabbit.

Authors:  Raza A; Muhammad G; Rahman S U; Rashid I; Hanif K; Atta A; Sharif S
Journal:  Iran J Vet Res       Date:  2015       Impact factor: 1.376

8.  5-O-Mycaminosyltylonolide antibacterial derivatives: design, synthesis and bioactivity.

Authors:  Akihiro Sugawara; Hitomi Maruyama; Sho Shibusawa; Hidehito Matsui; Tomoyasu Hirose; Ayumi Tsutsui; Robrecht Froyman; Carolin Ludwig; Johannes Koebberling; Hideaki Hanaki; Gerd Kleefeld; Satoshi Ōmura; Toshiaki Sunazuka
Journal:  J Antibiot (Tokyo)       Date:  2017-05-31       Impact factor: 2.649

9.  Intramammary expression and therapeutic effect of a human lysozyme-expressing vector for treating bovine mastitis.

Authors:  Huai-chang Sun; Fang-ming Xue; Ke Qian; Hao-xia Fang; Hua-lei Qiu; Xin-yu Zhang; Zhao-hua Yin
Journal:  J Zhejiang Univ Sci B       Date:  2006-04       Impact factor: 3.066

10.  Development of specific and rapid detection of bacterial pathogens in dairy products by PCR.

Authors:  M Chotár; B Vidová; A Godány
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.